Stent Coating Integrity of Durable and Biodegradable Coated Drug Eluting Stents

Journal of Interventional Cardiology

Volumn 29, Issue 5, 2016, Pages 483-490

  Yazdani, Saami K ^a,b   Sheehy, Alexander ^c   Pacetti, Stephen ^c   Rittlemeyer, Brandon ^b   Kolodgie, Frank D ^a   Virmani, Renu ^a  

^a CVPATH INSTITUTE   (United States)

^b University of South Alabama   (United States)

^c ABBOTT VASCULAR   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABLE IMPLANT; BIOLIMUS ELUTING CORONARY STENT; CONTROLLED STUDY; EVEROLIMUS ELUTING CORONARY STENT; FEMORAL ARTERY; ILIAC ARTERY; NONHUMAN; PACLITAXEL ELUTING CORONARY STENT; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; ANATOMIC MODEL; ANIMAL; CLASSIFICATION; CORONARY DISEASE; DEVICE FAILURE ANALYSIS; DEVICES; DISEASE MODEL; DRUG ELUTING STENT; MATERIALS TESTING; PROCEDURES; TIME FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANTINEOPLASTIC AGENT; BIOCOMPATIBLE COATED MATERIAL; BIODEGRADABLE PLASTIC; IMMUNOSUPPRESSIVE AGENT;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIODEGRADABLE PLASTICS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY DISEASE; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; EQUIPMENT FAILURE ANALYSIS; IMMUNOSUPPRESSIVE AGENTS; MATERIALS TESTING; MODELS, ANATOMIC; RABBITS; TIME FACTORS;

EID: 84976523980     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12303     Document Type: Article

References (29)

1. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48:193–202.
2. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: Importance of delayed healing. Arterioscler Thromb Vasc Biol 2007; 27:1500–1510.
3. Palmerini T, Biondi-Zoccai G, Stone GW Stent selection to minimize the risk of stent thrombosis. Curr Opin Cardiol 2014; 29:578–585.
4. Kipshidze NN, Tsapenko MV, Leon MB, et al. Update on drug-eluting coronary stents. Expert Rev Cardiovasc Ther 2005; 3:953–968.
5. Puskas JE, Munoz-Robledo LG, Hoerr RA, et al. Drug-eluting stent coatings. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009; 1:451–462.
6. Wiemer M, Butz T, Schmidt W, et al. Scanning electron microscopic analysis of different drug eluting stents after failed implantation: From nearly undamaged to major damaged polymers. Catheter Cardiovasc Interv 2010; 75:905–911.
7. Yazdani SK, Vorpahl M, Nakano M, et al. In vitro and in vivo characterisation of biodegradable polymer-based drug-eluting stent. EuroIntervention 2011; 7:835–843.
8. Hirlekar R, Patel M, Jain S, et al. Drug eluting coronary artery stents. Curr Drug Del 2010; 7:421–427.
9. Wessely R. New drug-eluting stent concepts. Nat Rev Cardiol 2010; 7:194–203.
10. Basalus MW, Tandjung K, van Westen T, et al. Scanning electron microscopic assessment of coating irregularities and their precursors in unexpanded durable polymer-based drug-eluting stents. Catheter Cardiovasc Interv 2012; 79:644–653.
11. Basalus MW, Ankone MJ, van Houwelingen GK, et al. Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. EuroIntervention 2009; 5:157–165.
12. Otsuka F, Cheng Q, Yahagi K, et al. Acute thrombogenicity of a durable polymer everolimus-Eluting stent relative to contemporary drug-Eluting stents with biodegradable polymer coatings assessed ex vivo in a swine shunt model. JACC Cardiovasc Interv 2015; 8:1248–1260.
13. Ding NI, Pacetti SD, Tang F-W, et al. Xience V stent design and rationale. J Interv Cardiol 2009; 22:S18–S27.
14. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008; 52:333–342.
15. Hwang CW, Levin AD, Jonas M, et al. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 2005; 111:1619–1626.
16. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004; 109:701–705.
17. Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation 2014; 129:211–223.
18. Basalus MW, Tandjung K, VANA AA, et al. Effect of oversized partial postdilatation on coatings of contemporary durable polymer-based drug-eluting stents: A scanning electron microscopy study. J Interv Cardiol 2011; 24:149–161.
19. Basalus MW, Joner M, von Birgelen C, et al. Polymer coatings on drug-eluting stents: Samson's hair and Achilles’ heel? EuroIntervention 2013; 9:302–305.
20. Yazdani SK, Sheehy A, Nakano M, et al. Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. J Invasive Cardiol 2013; 25:383–390.
21. Zhang Z, Guidoin R, King MW, et al. Removing fresh tissue from explanted polyurethane prostheses: Which approach facilitates physico-chemical analysis? Biomaterials 1995; 16:369–380.
22. Strickler F, Richard R, McFadden S, et al. In vivo and in vitro characterization of poly(styrene-b-isobutylene-b-styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. J Biomed Mater Res 2010; 92:773–782.
23. Dohany JE, Humphrey JS. Vinylidene fluoride polymers. In: Mark HF, Bikales NM, Overberger CG, Menges G, eds. Encyclopedia of Polymer Science and Engineering. vol. 17. New York: Wiley, 1989, pp. 532–548.
24. Brady, Jr. RR. Fluoropolymers. Chem Br 1990; 26:427–430.
25. Levy Y, Mandler D, Weinberger J, et al. Evaluation of drug-eluting stents’ coating durability-clinical and regulatory implications. J Biomed Mater Res B Appl Biomater 2009; 91:441–451.
26. Kao WJ, Hiltner A, Anderson JM, et al. Theoretical analysis of in vivo macrophage adhesion and foreign body giant cell formation on strained poly(etherurethane urea) elastomers. J Biomed Mater Res 1994; 28:819–829.
27. Zhao OH, Anderson JM, Hiltner A, et al. Theoretical analysis on cell size distribution and kinetics of foreign-body giant cell formation in vivo on polyurethane elastomers. J Biomed Mater Res 1992; 26:1019–1038.
28. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362:1663–1674.
29. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363:136–146.